Rethinking treatment for nervous system disorders
Empowering patients to live on their own terms

Who We Are

At its core, Eliem is motivated by the promise of helping people live happier, more fulfilling lives. The Eliem team channels its experience, energy and passion for improving patients’ quality of life by developing life-changing novel therapies for neuronal excitability disorders based on clinically validated mechanisms of action.

Our Approach: Optimizing Treatments for Neuronal Excitability Disorders

Tens of millions of people suffer from central and peripheral nervous system disorders, where an imbalance between excitation and inhibition has disrupted the homeostasis in affected neuronal networks. These disorders include a range of common conditions such as chronic pain, depression, epilepsy and anxiety. Currently available treatments for these conditions often fail to provide adequate control or relief, and they are often poorly tolerated, leaving people unable to live life on their own terms.

Developing improved treatments for patients requires a pragmatic and diligent approach. Equal parts rigorous and agile, the experienced Eliem team strives to make treatments that are more effective, safer and better tolerated than currently available treatments. Leveraging clinically validated mechanisms of action, we are moving steadily and efficiently to develop novel therapeutics for neuronal excitability disorders that deliver enhanced outcomes for patients.

Our Pipeline

Our two lead drug candidates have clinically validated mechanisms of action for neurological diseases and have demonstrated encouraging clinical and preclinical results. We are developing ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression and focal onset seizures. These compounds are designed to dramatically improve on the limitations of existing therapies with the potential to be best-in-class for these conditions with high unmet clinical needs.

Our Experienced Team

Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience to the company. The team not only shares an unparalleled determination and passion to help patients, but they also have a history of working together to successfully build companies and bring novel and effective therapies to market. Eliem is also advised by a Board with considerable neurology research and development experience and a strong track record of building successful companies.

The team’s combined expertise in neurological research, clinical development, commercialization and company building are critical for delivering on the promise of bringing innovative therapies to market to provide relief and hope for the millions of patients affected by neurological conditions.
Leadership Team
Board of Directors
Bob Azelby
President and Chief Executive Officer
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Erin Lavelle
Executive Vice President, Chief Operating Officer & Chief Financial Officer
James Bucher, J.D.
Executive Vice President & General Counsel
Amy Chappell, M.D.
Chief Medical Officer
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Andrew Levin, M.D., Ph.D.
(Chairman)
Bob Azelby
Judith Dunn, Ph.D.
Leone Patterson
Liam Ratcliffe, M.D., Ph.D.
Adam Rosenberg
Simon Tate

News

Eliem Therapeutics Reports Second Quarter Financial Results

SEATTLE and CAMBRIDGE, UK, –(BUSINESS WIRE) – September 13, 2021 – Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter ended June 30, 2021.

Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

SEATTLE, WASH. and CAMBRIDGE, UK, August 12, 2021 – Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems, today announced the closing of its initial public offering of 7,360,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 960,000 additional shares of common stock, at a public offering price of $12.50 per share.
Load More
09/13/2021
Eliem Therapeutics Reports Second Quarter Financial Results

On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months

Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash runway through late 2023

SEATTLE and CAMBRIDGE, UK, –(BUSINESS WIRE) – September 13, 2021 – Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter ended June 30, 2021.

“It has been an exciting year thus far for Eliem, highlighted by our successful initial public offering (IPO) that we completed in August,” said Bob Azelby, Eliem’s president and chief executive officer. “In the second quarter, we continued to advance enrollment on our two Phase 2a studies for ETX-810 in patients with chronic pain conditions. We also made excellent progress toward initiating three clinical studies for ETX-155 in depressive disorders and epilepsy. The proceeds from our IPO, along with the additional capital we raised in our Series B financing in May 2021, are expected to fund our operations through late 2023. We believe this funding will take us through multiple topline clinical data readouts across five different indications and also allows us to advance our preclinical pipeline. We remain committed to developing therapies targeting debilitating disorders that impact tens of millions of people worldwide every day.”

Recent Highlights and Upcoming Milestones

Initial public offering raised $92 million gross proceeds: In August 2021, the Company announced the public offering of 7,360,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase an additional 960,000 shares of common stock, at a public offering price of $12.50 per share. The Company received estimated net proceeds of $83.1 million from the IPO, after deducting underwriting discounts of $6.4 million and estimated offering costs of $2.5 million. The IPO was preceded by a Series B financing in May 2021 that raised gross proceeds of $60.0 million.

Program Updates and Milestones

ETX-810 in chronic pain:  ETX-810 is a novel new chemical entity prodrug of the bioactive lipid palmitoylethanolamide (PEA) that is currently being evaluated in two Phase 2a clinical trials in patients with diabetic peripheral neuropathic pain (DPNP) and lumbosacral radicular pain (LSRP), commonly referred to as sciatica. ETX-810 was designed to optimize the oral absorption and systemic exposure of PEA, which is believed to play a critical role in the regulation of neuroinflammation and pain signaling in chronic pain.

  • ETX-810 in DPNP. The Company is conducting a Phase 2a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the efficacy and safety of ETX-810 in adults with DPNP. The Company expects to have a topline data readout during the first half of 2022.
  • ETX-810 in LSRP.  The Company is conducting a Phase 2a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the efficacy and safety of ETX-810 in adults with LSRP. The Company expects to have a topline data readout during the first half of 2022.

ETX-155 in depression and epilepsy:  ETX-155 is a novel GABAA receptor positive allosteric modulator that Eliem plans to evaluate in patients with major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizure (FOS). ETX-155 was designed to have broad potency across both synaptic and extrasynaptic GABAA receptor subtypes. In Phase 1 clinical studies to date, ETX-155 was shown to be well tolerated with desirable pharmacokinetic properties, including no clinically meaningful food effect and at least a 24-hour half-life to enable once-a-day-dosing. The Company believes these attributes combine to position it well within the GABAA PAM therapeutic class.

  • ETX-155 in FOS.  The Company expects to initiate a single-arm, proof-of-concept Phase 1b trial in photosensitive epilepsy patients in the second half of 2021 with topline data expected by the first half of 2022.
  • ETX-155 in MDD.  The Company expects to initiate a randomized, placebo-controlled, Phase 2a proof-of-concept trial of ETX-155 in the second half of 2021 with first patient dosed in early 2022 and topline data expected in the first half of 2023.
  • ETX-155 in PMD.  The Company expects to initiate a randomized, placebo-controlled, Phase 2a proof-of-concept trial of ETX-155 in the second half of 2021 with first patient dosed in early 2022 and topline data expected in the first half of 2023.

Preclinical Pipeline:  The Company is progressing two preclinical programs currently in the discovery stage.

  • Kv7.2/3 in pain and epilepsy.  The lead preclinical program targets the Kv7.2/3 potassium channel that has been shown to play a role in stabilizing the membrane potential of neuronal cells and controlling neuronal excitability. The Company plans to nominate a clinical candidate in the second half of 2021.
  • Anxiolytic for generalized anxiety disorder (GAD).  The Company is also in early preclinical development of a novel, rapid-acting, non-sedating, non-addictive anxiolytic for the potential treatment of GAD. The Company plans to nominate a clinical candidate in 2022.

Second Quarter 2021 Financial Results

  • Cash Position:  Cash was $99.5 million as of June 30, 2021, as compared to $47.9 million as of March 31, 2021. This does not include an additional $83.1 million in net proceeds from the Company’s IPO in August 2021.
  • Research and Development (R&D) expenses:  R&D expenses were $5.8 million for the three months ended June 30, 2021, compared to $1.4 million for the same period in 2020.
  • General and Administrative (G&A) expenses:  G&A expenses were $2.9 million for the three months ended June 30, 2021, compared to $0.2 million for the same period in 2020.
  • Net loss:  Net loss was $8.7 million for the three months ended June 30, 2021, compared to $1.6 million for the same period in 2020.

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

https://eliemtx.com/

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements relating to: Eliem’s plans to initiate clinical trials of ETX-155 and the timing thereof; anticipated data readouts of ETX-810 and ETX-155 and the timing thereof; the progression of the Kv7.2/3 and next-generation anxiolytic preclinical programs; the sufficiency of Eliem’s current funds and anticipated cash runway through late 2023; and Eliem’s commitment to developing therapies targeting debilitating disorders. Words such as “on track,” “advance,” “progress,” “provides,” “runway,” “will,” “enable,” “expect,” “believe,” “plans,” “initiate,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Eliem’s current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the clinical, therapeutic and commercial value of ETX-810, ETX-155 and Eliem’s preclinical programs; risks related to the potential failure of ETX-810 and ETX-155 to demonstrate safety and efficacy in clinical testing; Eliem’s ability to initiate and conduct clinical trials and studies of ETX-810 and ETX-155 sufficient to achieve a positive completion; the availability of data at the expected times; Eliem’s ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Eliem’s preclinical and clinical development activities; the sufficiency of Eliem’s capital and other resources; risks and uncertainties related to Eliem’s compliance with applicable legal and regulatory requirements; market competition; changes in economic and business conditions; impacts on Eliem’s business due to health pandemics or other contagious outbreaks, such as the current COVID-19 pandemic; and other factors discussed under the caption “Risk Factors” in Eliem’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021. This filing, when available, is available on the SEC’s website at www.sec.gov. Additional information will also be set forth in Eliem’s other reports and filings it will make with the SEC from time to time. The forward-looking statements made in this press release speak only as of the date of this press release. Eliem expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Eliem’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investors:

Chris Brinzey
Westwicke, an ICR Company
chris.brinzey@westwicke.com
339.970.2843

Media:

Marites Coulter
Verge Scientific Communications
mcoulter@vergescientific.com
415.819.2214

Eliem Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(unaudited)

AssetsJune 30, 2021December 31, 2020
Current assets:  
Cash$99,482 $20,487
Prepaid expenses and other current assets 5,321 1,511
Total current assets$104,803 $21,998
Long-term assets 2,824 2,633
Total assets$107,627 $24,631
Liabilities, Redeemable Convertible Preferred Stock, and
   Stockholders’ Deficit
  
Current liabilities:  
Accounts payable 1,955 1,086
Accounts payable, related party  207
Accrued expenses 3,631 1,219
Accrued expenses, related party 127 
Redeemable convertible preferred stock tranche liability  551
Total current liabilities$5,713 $3,063
Total liabilities$5,713 $3,063
Commitments and contingencies  
Redeemable convertible preferred stock, $0.0001 par value,
   15,345,286 and 12,909,389 shares authorized, 15,345,279 and
   7,140,157 shares issued and outstanding with aggregate
   liquidation preference of $147,096 and $49,891 at June 30,
   2021 and December 31, 2020, respectively
 152,759 46,551
Stockholders’ deficit:  
Common stock, $0.0001 par value per share, 46,000,000 and
   40,000,000 shares authorized; 3,489,956 and 3,418,751
   shares issued and outstanding at June 30, 2021 and
   December 31, 2020, respectively
 1 1
Additional paid-in capital 4,610 3,152
Accumulated deficit (55,456) (28,136)
Total stockholders’ deficit (50,845) (24,983)
Total liabilities, redeemable convertible preferred stock,
   and stockholders’ deficit
$107,627 $24,631

Eliem Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(unaudited)

Three months ended June 30,Three months ended June 30,Six months ended June 30,Six months ended June 30,
 2021202020212020
Operating expenses:
Research and development$5,478$1,325 $9,751 $2,714
Research and development, related party 31535 703 269
General and administrative 2,914248 5,132 576
Total operating expenses 8,7071,608 15,586 3,559
Loss from operations (8,707)(1,608) (15,586)(3,559)
Other income (expense):    
Change in fair value of redeemable convertible preferred stock tranche liability  (11,718) 
Foreign currency gain (loss) (12)(23) (16)12
Total other income (expense) (12)(23) (11,734)12
Net loss and comprehensive loss$(8,719)$(1,631) $(27,320)$(3,547)
Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred stock dividends (2,141)(452) (3,226)(891)
Net loss attributable to common stockholders$(10,860)$(2,083) $(30,546)$(4,438)
Net loss per share attributable to common stockholders, basic and diluted$(3.11)$(1.12) $(8.80)$(2.39)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted 3,488,0171,859,703 3,472,086 1,857,617

< Show all news
08/12/2021
Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

SEATTLE, WASH. and CAMBRIDGE, UK, August 12, 2021 – Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems, today announced the closing of its initial public offering of 7,360,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 960,000 additional shares of common stock, at a public offering price of $12.50 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Eliem, were $92.0 million. All of the shares in the offering were sold by Eliem.

SVB Leerink, Evercore ISI, Stifel, and Guggenheim Securities acted as joint bookrunning managers for the offering.

Registration statements relating to these securities were filed with the Securities and Exchange Commission (“SEC”) and became effective on August 9, 2021. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. The offering was made only by means of a written prospectus, forming a part of the effective registration statements. Copies of the final prospectus relating to the initial public offering may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at 800-808-7525 ext. 6105 or by email at syndicate@svbleerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Investor Contact:

Chris Brinzey
Westwicke
chris.brinzey@westwicke.com
339.970.2843

Media Contact:

Marites Coulter
VERGE Scientific Communications
mcoulter@vergescientific.com
415.819.2214

< Show all news
08/09/2021
Eliem Therapeutics Announces Pricing of Initial Public Offering

SEATTLE, WASH. and CAMBRIDGE, UK, August 9, 2021 – Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced the pricing of its initial public offering of 6,400,000 shares of common stock at a public offering price of $12.50 per share. All of the shares are being offered by Eliem. Eliem has granted the underwriters a 30-day option to purchase up to an additional 960,000 shares of common stock at the initial public offering price. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Eliem, are expected to be $80.0 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock.

The shares are expected to begin trading on the Nasdaq Global Market on August 10, 2021 under the ticker symbol “ELYM.” The offering is expected to close on August 12, 2021, subject to the satisfaction of customary closing conditions.

SVB Leerink, Evercore ISI, Stifel, and Guggenheim Securities are acting as joint bookrunning managers for the offering.

Registration statements relating to these securities were filed with the Securities and Exchange Commission (“SEC”) and became effective on August 9, 2021. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. The offering will be made only by means of a written prospectus, forming a part of the effective registration statements. Copies of the final prospectus relating to the initial public offering, when available, may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at 800-808-7525 ext. 6105 or by email at syndicate@svbleerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Investor Contact:

Chris Brinzey
Westwicke
chris.brinzey@westwicke.com
339.970.2843

Media Contact:

Marites Coulter
VERGE Scientific Communications
mcoulter@vergescientific.com
415.819.2214

< Show all news
05/24/2021
Eliem Therapeutics Announces $60 Million Series B Financing

Advances two clinical programs through topline data across four indications

Progresses two preclinical programs to potential lead candidate selection

Brings total funding since inception to $140 million

SEATTLE and CAMBRIDGE, UK –(BUSINESS WIRE) – May 24, 2021 – Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems, announced the closing of a $60 million Series B financing. The financing round was led by Intermediate Capital Group (ICG) and RA Capital Management and included participation from Access Biotechnology, Samlyn Capital, Acorn Bioventures and LifeArc. Eliem plans to use the proceeds to advance its two lead clinical-stage product candidates, ETX-810 and ETX-155, through topline data across four different indications in patients with chronic pain, depressive disorders, and epilepsy, as well as to advance its two preclinical-stage programs to selection of clinical development candidates.

“We are excited to have the continued support of our investment group, and we welcome our new investors to this latest financing round,” said Bob Azelby, President and Chief Executive Officer of Eliem Therapeutics. “This financing builds upon $80 million of prior funding, allowing for the advancement of our mission to develop life-changing therapies for debilitating neuronal excitability disorders. These disorders impact tens of millions of people worldwide and represent large commercial market opportunities. With this capital, we will continue to execute our strategy to develop differentiated small molecule new chemical entities, based on clinically validated mechanisms of action with well-established clinical and regulatory endpoints.”  

Simon Tate, Managing Director of ICG, said, “We are delighted to lead this funding round; Eliem Therapeutics is a truly exciting company and our investment reflects the overwhelming confidence we have in the team and its differentiated pipeline of clinical assets.”

Eliem is currently evaluating ETX-810, an investigational novel prodrug of the bioactive lipid palmitoylethanolamide, in two Phase 2a clinical trials in patients with diabetic peripheral neuropathic pain and lumbosacral radicular pain, with topline data expected in the first half of 2022. For its second lead product candidate, ETX-155, an investigational novel GABAA receptor positive allosteric modulator, Eliem plans to initiate two Phase 2a clinical trials, in patients with major depressive disorder and hormone-related depressive disorders, which are expected to report topline data in the second half of 2022 and the first half of 2023, respectively. In addition, for ETX-155, Eliem intends to initiate a Phase 1b clinical trial in patients with photosensitive epilepsy, that is expected to report topline data by the first half of 2022. Eliem is also progressing two preclinical programs currently in the advanced discovery stage: a novel Kv7.2/3 potassium channel opener for the potential treatment of pain and epilepsy, and a novel 2,3-benzodiazepine anxiolytic for the potential treatment of generalized anxiety disorder and depression.

About Eliem Therapeutics, Inc. 

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. Eliem is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. Through its Series B financing, Eliem has raised an aggregate of $140 million from financings, including those of predecessor companies.

https://eliemtx.com

About RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.

https://racap.com/

About Access Biotechnology

Access Biotechnology is the life science investment arm of Access Industries, a privately-held industrial group with long-term holdings throughout the world. The firm leverages medical and scientific expertise to rigorously evaluate each new opportunity and collaborate with company stakeholders to meaningfully impact human health. Its investment strategy is broad, long term, and aims to enable truly innovative therapeutic platforms and products across three key stages: company foundation, technology translation, and company expansion.

http://accessbio-tech.com

About Intermediate Capital Group

ICG provides capital to help companies grow. We are a global alternative asset manager with over 30 years’ history, managing €47.2bn of assets in private debt, credit and equity, principally in closed-end funds.*

We develop long-term relationships with our business partners to deliver value for shareholders, clients and employees, and use our position of influence to benefit the environment and society. We operate across four strategic asset classes: corporate, capital market, real asset and secondary investments. In addition to growing existing strategies, we innovate and pioneer new strategies where the market opportunity exists. ICG is listed on the London Stock Exchange (ticker symbol: ICP). Further details are available at www.icgam.com. You can follow ICG on LinkedIn.

*as at 31 December 2020

https://www.icgam.com/

Acorn Bioventures 

Acorn Bioventures invests across stages in small-cap public and private biotechnology companies focused on bringing novel innovative medicines to patients. Their investment flexibility allows them to provide value across the entire spectrum from seed financings, cross-over financings, IPOs, registered direct offerings, PIPEs, open market purchases, etc. Acorn Bioventures’ investment process is based on fundamental research. They look for paradigm changing medical therapies, undiscovered or underappreciated assets, backed by outstanding teams.

www.acornbioventures.com

About LifeArc

LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. LifeArc has a number of different funding mechanisms to invest in promising innovation for the benefit of patients. Our Philanthropic Fund provides grants to support medical research projects focused on the translation of rare diseases research. Our Early Ventures investment strategy builds on our Seed Fund portfolio of start-up companies; investing in innovative new modalities, technologies and translational research that have the potential to generate impact for patients and income that will enable us to drive further innovation.

Investors

Chris Brinzey 

Westwicke, an ICR Company

chris.brinzey@westwicke.com

339-970-2843

Media

Marites Coulter

Verge Scientific

mcoulter@vergescientific.com

415.819.2214

< Show all news
03/25/2021
Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders

Company advancing potentially “best-in-class” drug candidates with clinically validated mechanisms of action

Clinical programs addressing large markets with substantial unmet needs: chronic pain, depression, epilepsy, and anxiety

Leadership team brings decades of neuroscience R&D and commercialization experience

SEATTLE and CAMBRIDGE, UK, 25 March 2021 – Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80 million in financing since its inception in 2019. With funding from RA Capital Management, Access Biotechnology, and Intermediate Capital Group (ICG), Eliem aims to develop and commercialize therapies treating neuronal excitability disorders such as chronic pain, depression, epilepsy, and anxiety – conditions that cause deep suffering for tens of millions of people each day.

The company is progressing two clinical stage assets with clinically validated mechanisms of action for neurological diseases. ETX-810, an investigational new chemical entity (NCE) for chronic pain, which acts via the palmitoylethanolamide (PEA) pathway, is being evaluated in two Phase 2a trials in lumbosacral radicular pain (chronic sciatica) and diabetic peripheral neuropathic pain. ETX-155, an investigational next generation neuroactive steroid NCE that acts as a GABAA positive allosteric modulator (PAM), is being evaluated in Phase 1 studies with plans for 2021 trial initiations in multiple indications, including major depressive disorder (MDD), hormone-related mood disorders, and focal onset seizures (FOS).

“Most patients with chronic pain and other neuronal excitability disorders struggle immensely to manage their condition with currently available treatments,” said Eliem’s President and Chief Executive Officer, Bob Azelby. “For many of these patients, the inability to execute day-to-day activities is devastating, and living a normal life can seem out of reach. We are confident that our highly experienced and dedicated team is developing treatments that can achieve meaningfully better clinical outcomes for patients, offering them the opportunity to lead the lives they were meant to live.”

Azelby most recently served as President and Chief Executive Officer of Alder BioPharmaceuticals, and before that, as Executive Vice President and Chief Commercial Officer at Juno Therapeutics. At Eliem, he is joined by a highly skilled management team – based in Seattle and Cambridge, UK – that collectively has decades of foundational experience at companies such as Amgen, GlaxoSmithKline, and Lilly as well as small biotech companies such as Alder, Juno, Exelixis, and Convergence.

“The Eliem management team knows how to develop safe and well tolerated drugs that work; and understands how to efficiently bring those treatments to patients in need,” said Andrew Levin, M.D., Ph.D., Managing Director at RA Capital Management, and Eliem co-founder and Chairman of the Board of Directors. “With an exceptionally strong and experienced leadership team, and promising preclinical and clinical data, the company has a real opportunity to transform clinically validated mechanisms of action into ‘best-in-class’ medicines.”

Eliem’s Pipeline

Eliem is currently evaluating two of its programs in clinical trials:

  • – ETX-810 is an investigational novel first-in-class, oral, non-opioid NCE being developed for chronic pain conditions.
    • Despite a massive global chronic pain market that is expected to pass $29 billion in the next decade, less than half of patients achieve a 50 percent reduction in their pain with currently approved therapies. In addition to limited efficacy, the current standard of care is hindered by dose-limiting side effects, including dizziness, sedation, gastrointestinal disturbances, as well as concerns over abuse liability.  
    • ETX-810 exerts its therapeutic effects through the PEA pathway, which is known to broadly modulate neuroinflammation and pain signaling. PEA is an endogenous bioactive lipid that has been validated as a therapeutic agent in more than 25 clinical trials across a range of chronic pain indications, where it has consistently demonstrated statistically significant reductions in pain with favorable safety and tolerability. Leveraging this data, ETX-810 was designed to significantly improve the oral bioavailability and systemic exposure of PEA to maximize the therapeutic effect. In addition to its potential to significantly reduce chronic pain, ETX-810 has no known drug-to-drug interactions or abuse liability, and in clinical testing demonstrates an encouraging safety and tolerability profile.
  • – ETX-155 is an investigational oral, next generation neuroactive steroid NCE that acts as a GABAA PAM and is being evaluated for use in depression and epilepsy.
    • MDD affects approximately 35 million adults globally, causing significant impairment to daily life. While there are effective therapies available for individuals suffering from MDD, there is considerable variability in patient responsiveness. There is a pressing need for safe, well tolerated, and rapidly acting antidepressants that reliably provide clinical improvement faster than the up to 6 weeks associated with standard of care SSRIs/SNRIs.
    • ETX-155 demonstrates dual synaptic and extrasynaptic receptor activity with an approximate 24-hour half-life and no clinically meaningful food effect. Preclinical and Phase 1 clinical data demonstrate the potential for ETX-155 to be a “best-in-class” treatment for multiple neuronal excitability disorders.

Eliem is progressing a pipeline of novel preclinical candidates with two programs currently in advanced discovery stage. As with the lead clinical programs, the preclinical programs leverage novel chemical insights and clinically validated mechanisms of action.

Eliem’s lead preclinical program is a Kv7.2/3 channel opener. This mechanism has been validated through regulatory approvals of multiple first generation Kv7.2/3 channel openers for the treatment of epilepsy and pain. These molecules showed powerful clinical efficacy but subsequently had to be withdrawn from the market due to significant safety issues. Eliem is designing its NCE to harness the efficacy of the Kv7.2/3 channel mechanism while significantly improving the safety and tolerability profile. The company expects to nominate a clinical candidate in the second half of 2021.

Leadership Team

Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience; and is advised by a Board with considerable neurology research and development experience and a strong track record of building successful companies.

Company Founders

  • Andrew Levin, M.D., Ph.D. – Managing Director, RA Capital Management, L.P.
  • Valerie Morisset, Ph.D. – Executive Vice President, R&D and Chief Scientific Officer

Company Leaders

  • Bob Azelby – President and Chief Executive Officer
  • Valerie Morisset, Ph.D. – Executive Vice President, R&D and Chief Scientific Officer
  • Erin Lavelle – Executive Vice President, Chief Operating Officer and Chief Financial Officer
  • James Bucher, J.D. – Executive Vice President and General Counsel
  • Amy Chappell, M.D. – Chief Medical Officer
  • Jo Palmer-Phillips, Ph.D. – Chief Development Officer

Board of Directors

  • Andrew Levin, M.D., Ph.D. (Chairman) – Managing Director, RA Capital Management, L.P.
  • Bob Azelby – President and Chief Executive Officer
  • Judith Dunn, Ph.D. – President of Research and Development, Fulcrum Therapeutics
  • Leone Patterson – President and Chief Financial Officer, Adverum Biotechnologies
  • Liam Ratcliffe, M.D., Ph.D. – Head of Access Biotechnology
  • Adam Rosenberg – Venture Partner, RA Capital Management, L.P.
  • Simon Tate – Managing Director, Intermediate Capital Group (ICG)

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for neuronal excitability disorders with the goal of restoring balance in both the peripheral and central nervous systems to help patients live on their own terms. Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing life-changing novel therapies for disorders such as chronic pain, depression, epilepsy, focal onset seizures, and anxiety – conditions that make simple daily activities challenging for impacted patients. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

https://eliemtx.com/

About RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.

https://racap.com/

About Access Biotechnology

Access Biotechnology is the life science investment arm of Access Industries, a privately-held industrial group with long-term holdings throughout the world. The firm leverages medical and scientific expertise to rigorously evaluate each new opportunity and collaborate with company stakeholders to meaningfully impact human health. Its investment strategy is broad, long term, and aims to enable truly innovative therapeutic platforms and products across three key stages: company foundation, technology translation, and company expansion.

http://accessbio-tech.com

About Intermediate Capital Group

ICG provides capital to help companies grow. We are a global alternative asset manager with over 30 years’ history, managing €47.2bn of assets in private debt, credit and equity, principally in closed-end funds.*

We develop long-term relationships with our business partners to deliver value for shareholders, clients and employees, and use our position of influence to benefit the environment and society. We operate across four strategic asset classes: corporate, capital market, real asset and secondary investments. In addition to growing existing strategies, we innovate and pioneer new strategies where the market opportunity exists. ICG is listed on the London Stock Exchange (ticker symbol: ICP). Further details are available at www.icgam.com. You can follow ICG on LinkedIn.

*as at 31 December 2020

https://www.icgam.com/

Contacts

Media

Sarah Sutton
Finsbury Glover Hering (FGH)
sarah.sutton@fgh.com
518-932-3680

Ben Waldron
Finsbury Glover Hering (FGH)
ben.waldron@fgh.com
347-622-3740

< Show all news

Careers

We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.

We’d love to connect.

Open Positions
Senior Manager – Technical Accounting and SEC Reporting
Senior Manager – Technical Accounting and SEC Reporting

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We are looking for a Senior Manager – Technical Accounting and SEC Reporting to join our growing global Accounting team. This is a crucial role that will assist in overseeing financial reporting in our transition to a public company. This role will report to the VP of Accounting and work with key internal and external stakeholders to deliver timely internal and external reporting in accordance with GAAP.

Responsibilities:

  • Manage SEC filings and supporting documents, including Form 10-K, 10-Q, proxy statements, and other required form filings
  • Independently research and analyze accounting issues and disclosure requirements in accordance with US GAAP and SEC reporting requirements
  • Preparing cash flows, stockholders’ rollforward, EPS calculation, stock-based compensation, and accounting for non-routine transactions
  • Complete disclosure checklists to ensure all disclosure requirements are met; research disclosure requirements and keep abreast of new pronouncements impacting disclosures; establish a repository of internal practices and peer company disclosures
  • Monitor proposed and enacted accounting pronouncements that affect the Company and make recommendations on implementing changes/compliance
  • Collaborate with finance, investor relations and legal on external stakeholder financial communications
  • Review XBRL tagging in connection with Form 10-K and 10-Q filings
  • Ensure compliance with Sarbanes-Oxley (SOX) controls as it pertains to financial reporting and
    equity processes
  • Assist with the implementation of accounting and other systems for better financial and operational reporting and an improved control environment
  • Assist in various ongoing and ad-hoc projects or initiatives as needed

Experience:

  • Bachelor’s degree in Accounting/Finance and CPA required
  • Strong, current understanding of US GAAP and SEC reporting rules and regulations
  • 6+ years of experience in accounting; including Big 4 public accounting experience and
    experience with financial reporting in a public company
  • Strong project management skills and the ability to manage a process and team to multi-task,
    work under pressure, and meet deadlines in a fast-paced work environment
  • Active Disclosure and XBRL experience preferred
  • Strong organizational, verbal, and written communication skills are a must
  • Accounting research and problem-solving skills required
  • Ability to build strong relationships with internal and external business partners
  • Ability to operate independently and as part of a larger functional team
  • Proficient with Microsoft Office – Word, Excel, and PowerPoint
  • Experience with NetSuite is a plus

Benefits

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Qualified candidates are encouraged to forward their resume to CareersUS@eliemtx.com

Senior Corporate Counsel
Senior Corporate Counsel

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

The Senior Corporate Counsel is a newly created position at Eliem and will play a key role in the company’s legal department. Reporting directly to Eliem’s Executive Vice President and General Counsel, they will enjoy a varied role advising the company’s teams in the United States and United Kingdom. The Senior Corporate Counsel will work on a broad range of contracts, general corporate, compliance, governance, securities, human resources, benefits, and business development matters, and provide effective, business-focused legal advice and counsel to stakeholders across the organization. The level of counseling requires a deep understanding of life sciences businesses and related legal issues, as well as outstanding drafting and negotiation skills. The Senior Corporate Counsel may also provide support on various intellectual property matters as needed.

Responsibilities:

  • Lead the drafting, review, interpretation, negotiation and execution of all routine life sciences agreements, such as confidentiality, consulting, services, clinical trial, manufacturing, license and vendor agreements, while appropriately engaging the Executive Vice President and General Counsel for complicated terms or negotiations
  • Prepare materials for the Board and its Committees, including drafting minutes, policies, plan documents and additional materials, and helping to ensure compliance with applicable corporate governance requirements
  • Provide legal support for all aspects of financing and business development transactions
  • Provide legal support on employment matters, compensation, equity and benefit plans
  • Provide legal support in evaluating, advising on and handling corporate securities and SEC
    reporting and compliance matters, including SEC periodic reports, proxy statements and registration statements
  • Assist with a variety of other in-house legal matters, as requested by the Executive Vice President and General Counsel
  • Work with outside counsel and other advisors, as necessary
  • Interact with colleagues in the United States and United Kingdom on a daily basis, which will
    involve flexibility regarding time zones and working hours

Requirements:

  • Juris Doctorate (JD) degree from ABA accredited law school required
  • 7+ years of relevant corporate legal experience
  • In-house experience preferably at a pharma/biotech company
  • Experience at a law firm with a sophisticated general corporate, contracts, corporate
    governance and securities practice is preferred
  • Experience with SEC and NASDAQ compliance
  • Experience with life sciences patent and other intellectual property matters is a plus
  • Experience at companies with international operations a plus
  • Proven ability to identify emerging risks and trends, analyze and think strategically about
    complex risk issues and deliver solutions-oriented advice and solutions to mitigate or manage such risks

Skill and Knowledge:

  • Maintains the highest levels of ethics and integrity
  • Excellent written, oral, and presentation skills
  • Proven ability to work with all levels of management and the general workforce
  • Strong customer service and problem-solving skills
  • Demonstrated ability to partner effectively with others in addressing complex issues
  • Strong influencing skills and business judgment
  • Strong organizational and time management skills
  • Motivated, self-starter with ability to appropriately prioritize issues and allocate resources
  • Strategic, innovative and detail-oriented
  • Ability to work in an international organization across different time zones
  • Periodic travel in the United States and United Kingdom is required

Benefits

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Qualified candidates are encouraged to forward their resume to CareersUS@eliemtx.com

Accounts Payable Staff Accountant
Accounts Payable Staff Accountant

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases.  Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions.  The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering.  The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We are looking for an Accounts Payable Staff Accountant to join our growing global Accounting team. This new position is responsible for managing the global accounts payable function, including the timely processing, verification, tracking, reporting, and payment of all approved invoices.  Additionally, the Accounts Payable Staff Accountant will be recording journal entries into the company’s ERP system, performing account reconciliations, and assist in other accounting projects.  The Accounts Payable Staff Accountant must be self-motivated with an outstanding work ethic. The ideal candidate will have prior UK VAT experience, excellent communication and organizational skills, be able to work with cross-functional teams. As a results-oriented professional the Accounts Payable Staff Accountant will report directly to the Controller.

Responsibilities:

  • Full cycle global accounts payable (entering invoices, processing, paying invoices).  This includes USD and GBP invoices
  • Verify the accuracy of vendor invoices and employee expense reimbursements
  • Manage A/P inbox, responding timely to internal and external emails
  • Reconcile A/P accounts and vendor statements, including researching, conducting phone calls and correcting discrepancies
  • Maintain W-9 records and prepare annual 1099 reports
  • Coordinate monthly reconciliation of corporate credit cards
  • Assist with month-end close, including posting journal entries and preparing account reconciliations for accounts such as: cash, AP, expense accruals, prepaids, and fixed assets
  • Identify, track, and properly account for prepaid expenses
  • Assist with gathering documents to support auditors’ requests, when needed
  • Support the accounting team on special projects and other responsibilities as needed
  • Adhere to and maintain internal control processes surrounding vendor management and invoice processing
  • Assist with special projects, initiatives, and system/process improvements as needed
  • Ability to streamline processes and implement automation whenever possible

Experience/Skills:

  • Bachelor’s degree in Finance or Accounting (preferred)
  • Minimum 2 years of Accounts Payable experience
  • Experience processing foreign currency invoices required, with UK VAT experience highly preferred
  • Basic accounting knowledge and understanding of debits and credits
  • Strong organization and prioritization skills
  • Strong verbal and written communication, both with internal and external stakeholders
  • Ability to work independently and as part of a team, with emphasis on accuracy and timeliness
  • Ability to work successfully across international time zones, which may include working at non-standard business hours
  • Strong problem-solving skills, basic accounting principles knowledge, documentation skills, research and resolution skills, data analysis and multi-tasking skills
  • Proficiency in Microsoft Office products with advanced Excel skills

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options. Qualified candidates are encouraged to forward their resumes to CareersUS@eliemtx.com.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Accounts Payable Staff Accountant

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases.  Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions.  The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering.  The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We are looking for an Accounts Payable Staff Accountant to join our growing global Accounting team. This new position is responsible for managing the global accounts payable function, including the timely processing, verification, tracking, reporting, and payment of all approved invoices.  Additionally, the Accounts Payable Staff Accountant will be recording journal entries into the company’s ERP system, performing account reconciliations, and assist in other accounting projects.  The Accounts Payable Staff Accountant must be self-motivated with an outstanding work ethic. The ideal candidate will have prior UK VAT experience, excellent communication and organizational skills, be able to work with cross-functional teams. As a results-oriented professional the Accounts Payable Staff Accountant will report directly to the Controller.

Responsibilities:

  • Full cycle global accounts payable (entering invoices, processing, paying invoices).  This includes USD and GBP invoices
  • Verify the accuracy of vendor invoices and employee expense reimbursements
  • Manage A/P inbox, responding timely to internal and external emails
  • Reconcile A/P accounts and vendor statements, including researching, conducting phone calls and correcting discrepancies
  • Maintain W-9 records and prepare annual 1099 reports
  • Coordinate monthly reconciliation of corporate credit cards
  • Assist with month-end close, including posting journal entries and preparing account reconciliations for accounts such as: cash, AP, expense accruals, prepaids, and fixed assets
  • Identify, track, and properly account for prepaid expenses
  • Assist with gathering documents to support auditors’ requests, when needed
  • Support the accounting team on special projects and other responsibilities as needed
  • Adhere to and maintain internal control processes surrounding vendor management and invoice processing
  • Assist with special projects, initiatives, and system/process improvements as needed
  • Ability to streamline processes and implement automation whenever possible

Experience/Skills:

  • Bachelor’s degree in Finance or Accounting (preferred)
  • Minimum 2 years of Accounts Payable experience
  • Experience processing foreign currency invoices required, with UK VAT experience highly preferred
  • Basic accounting knowledge and understanding of debits and credits
  • Strong organization and prioritization skills
  • Strong verbal and written communication, both with internal and external stakeholders
  • Ability to work independently and as part of a team, with emphasis on accuracy and timeliness
  • Ability to work successfully across international time zones, which may include working at non-standard business hours
  • Strong problem-solving skills, basic accounting principles knowledge, documentation skills, research and resolution skills, data analysis and multi-tasking skills
  • Proficiency in Microsoft Office products with advanced Excel skills

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options. Qualified candidates are encouraged to forward their resumes to CareersUS@eliemtx.com.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Senior Corporate Counsel

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

The Senior Corporate Counsel is a newly created position at Eliem and will play a key role in the company’s legal department. Reporting directly to Eliem’s Executive Vice President and General Counsel, they will enjoy a varied role advising the company’s teams in the United States and United Kingdom. The Senior Corporate Counsel will work on a broad range of contracts, general corporate, compliance, governance, securities, human resources, benefits, and business development matters, and provide effective, business-focused legal advice and counsel to stakeholders across the organization. The level of counseling requires a deep understanding of life sciences businesses and related legal issues, as well as outstanding drafting and negotiation skills. The Senior Corporate Counsel may also provide support on various intellectual property matters as needed.

Responsibilities:

  • Lead the drafting, review, interpretation, negotiation and execution of all routine life sciences agreements, such as confidentiality, consulting, services, clinical trial, manufacturing, license and vendor agreements, while appropriately engaging the Executive Vice President and General Counsel for complicated terms or negotiations
  • Prepare materials for the Board and its Committees, including drafting minutes, policies, plan documents and additional materials, and helping to ensure compliance with applicable corporate governance requirements
  • Provide legal support for all aspects of financing and business development transactions
  • Provide legal support on employment matters, compensation, equity and benefit plans
  • Provide legal support in evaluating, advising on and handling corporate securities and SEC
    reporting and compliance matters, including SEC periodic reports, proxy statements and registration statements
  • Assist with a variety of other in-house legal matters, as requested by the Executive Vice President and General Counsel
  • Work with outside counsel and other advisors, as necessary
  • Interact with colleagues in the United States and United Kingdom on a daily basis, which will
    involve flexibility regarding time zones and working hours

Requirements:

  • Juris Doctorate (JD) degree from ABA accredited law school required
  • 7+ years of relevant corporate legal experience
  • In-house experience preferably at a pharma/biotech company
  • Experience at a law firm with a sophisticated general corporate, contracts, corporate
    governance and securities practice is preferred
  • Experience with SEC and NASDAQ compliance
  • Experience with life sciences patent and other intellectual property matters is a plus
  • Experience at companies with international operations a plus
  • Proven ability to identify emerging risks and trends, analyze and think strategically about
    complex risk issues and deliver solutions-oriented advice and solutions to mitigate or manage such risks

Skill and Knowledge:

  • Maintains the highest levels of ethics and integrity
  • Excellent written, oral, and presentation skills
  • Proven ability to work with all levels of management and the general workforce
  • Strong customer service and problem-solving skills
  • Demonstrated ability to partner effectively with others in addressing complex issues
  • Strong influencing skills and business judgment
  • Strong organizational and time management skills
  • Motivated, self-starter with ability to appropriately prioritize issues and allocate resources
  • Strategic, innovative and detail-oriented
  • Ability to work in an international organization across different time zones
  • Periodic travel in the United States and United Kingdom is required

Benefits

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Qualified candidates are encouraged to forward their resume to CareersUS@eliemtx.com

Senior Manager – Technical Accounting and SEC Reporting

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We are looking for a Senior Manager – Technical Accounting and SEC Reporting to join our growing global Accounting team. This is a crucial role that will assist in overseeing financial reporting in our transition to a public company. This role will report to the VP of Accounting and work with key internal and external stakeholders to deliver timely internal and external reporting in accordance with GAAP.

Responsibilities:

  • Manage SEC filings and supporting documents, including Form 10-K, 10-Q, proxy statements, and other required form filings
  • Independently research and analyze accounting issues and disclosure requirements in accordance with US GAAP and SEC reporting requirements
  • Preparing cash flows, stockholders’ rollforward, EPS calculation, stock-based compensation, and accounting for non-routine transactions
  • Complete disclosure checklists to ensure all disclosure requirements are met; research disclosure requirements and keep abreast of new pronouncements impacting disclosures; establish a repository of internal practices and peer company disclosures
  • Monitor proposed and enacted accounting pronouncements that affect the Company and make recommendations on implementing changes/compliance
  • Collaborate with finance, investor relations and legal on external stakeholder financial communications
  • Review XBRL tagging in connection with Form 10-K and 10-Q filings
  • Ensure compliance with Sarbanes-Oxley (SOX) controls as it pertains to financial reporting and
    equity processes
  • Assist with the implementation of accounting and other systems for better financial and operational reporting and an improved control environment
  • Assist in various ongoing and ad-hoc projects or initiatives as needed

Experience:

  • Bachelor’s degree in Accounting/Finance and CPA required
  • Strong, current understanding of US GAAP and SEC reporting rules and regulations
  • 6+ years of experience in accounting; including Big 4 public accounting experience and
    experience with financial reporting in a public company
  • Strong project management skills and the ability to manage a process and team to multi-task,
    work under pressure, and meet deadlines in a fast-paced work environment
  • Active Disclosure and XBRL experience preferred
  • Strong organizational, verbal, and written communication skills are a must
  • Accounting research and problem-solving skills required
  • Ability to build strong relationships with internal and external business partners
  • Ability to operate independently and as part of a larger functional team
  • Proficient with Microsoft Office – Word, Excel, and PowerPoint
  • Experience with NetSuite is a plus

Benefits

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Qualified candidates are encouraged to forward their resume to CareersUS@eliemtx.com

Contact Us

MEDIA
INVESTOR RELATIONS
HUMAN RESOURCES
PARTNERING
Eliem Therapeutics, Inc.
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053

Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT